Lifesciences@Work : We help scientists build their business


Our focus is on drugs that target late-stage activation of the complement pathway (MAC formation): an innate part of the immune system. A number of candidates in our drug pipeline show efficacy in animal models of peripheral nerve degeneration and multiple sclerosis. We are committed to testing these candidates in other animal models of acute or chronic nerve degeneration to identify and exploit the full potential of these compounds. Given the high cost of drug development, Regenesance BV not only develops new drugs, but is also committed to discovering drugs approved for other medical uses in our therapy area (“drug repositioning”).